Morgan Stanley Reiterates Underweight on Bristol-Myers Squibb, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has reiterated an 'Underweight' rating on Bristol-Myers Squibb (BMY) and maintained a price target of $59.
July 11, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has reiterated an 'Underweight' rating on Bristol-Myers Squibb, indicating a negative outlook for the stock.
The 'Underweight' rating from Morgan Stanley suggests that they expect Bristol-Myers Squibb's stock to underperform compared to other stocks in the market. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100